Subjects currently being treated with a CYP 2C9, CYP 2C8, CYP 2C19, CYP 2D6, and P-gp substrate with a narrow therapeutic index.
Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor
Patients who requires treatment with a strong cytochrome P450 (CYP) family 3, subfamily A (3A) inhibitor
For cohort 2 (MCL) only: strong CYP3A4 inducers/inhibitors within 14 days prior to day 1 of protocol therapy and/or requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor
Use of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4.
Requires treatment with a strong cytochrome P(CYP)450 3A inhibitor OR subjects who have received a strong cytochrome P(CYP)450 3A inhibitor within 7 days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYP 450 3A inhibitor
Use of a moderate or strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 within 7 days prior to the expected start of ibrutinib therapy.
Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
Current use of a strong cytochrome P450 (CYP) 3A4/5 inhibitor or inducer
Requires treatment with a strong cytochrome (CYP) 3A4/5 inhibitor
Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitors or inducer
Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor/inducers
Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor
Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor
Requires treatment with a strong cytochrome P450 (CYP), family 3, subfamily A (3A) inhibitor
Requires treatment with a strong cytochrome P450 (CYP) family 3, subfamily A (3A) inhibitor
Requirement to receive treatment with a strong cytochrome P450 (CYP) 3A inhibitor
Requires treatment with strong cytochrome P450 (CYP)3A4/5 inhibitors, unless previously approved by sponsor
Current treatment with a strong cytochrome P450 (CYP) 3A4 inhibitor or inducer (EIAEDs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed)
Subjects who received a strong cytochrome P450 (CYP) 3A inhibitor within 7 days prior to the first dose of ibrutinib or subjects who require continuous treatment with a strong CYP 450 3A inhibitor
Concurrent use of known cytochrome P450 3A4 (CYP 3A4) inhibiting or activating medications
Use of strong CYP inhibitors or drugs that carry a definite risk of torsades de pointes. Please consult the medication prescribing information prior to prescribing new medications to make sure that the new medication is not a strong CYP inhibitor. Moderate CYP inhibitors should be avoided if possible
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
Strong inhibitors of cytochrome P450 3A4 (CYP3A4) are prohibited; grapefruit juice is an inhibitor of CYP450 and should not be taken with pazopanib
Patients who require treatment with a strong cytochrome P450 (CYP) 3A inhibitor
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
Patients who require treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor
Treatment with a strong cytochrome P450 (CYP) 3A inhibitor.
Requires treatment with a strong cytochrome P450 (CYP) family 3, subfamily A, polypeptide 4/5 (3A4/5) inhibitor
Requirement for treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor
Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor
Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.
Patients are not eligible if they require treatment with a strong cytochrome P450 (CYP) family 3, subfamily A (3A) inhibitor
Any previous exposure to a CYP17 (17?-hydroxylase/C17,20-lyase) inhibitor;
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
Patients who requires treatment with a potent cytochrome P450 (CYP) 3A inhibitor or inducer
Concurrent use of known cytochrome P450 3A4 (CYP 3A4) inhibiting or activating medications
Concurrent use of a strong cytochrome P450 (CYP)3A4/5 inhibitor
Requires chronic treatment with strong cytochrome P450 (CYP)3A inhibitors
Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor
Use of strong cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks before the first dose of study drug.
Use of strong cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks before the first dose of study drug.
Treatment with a strong cytochrome P450 (CYP) 3A inhibitor
Patients should agree to avoid grapefruit juice which is a major inhibitor of cytochrome P-450 (CYP)3A4
Requires treatment with a strong cytochrome P450 (CYP) family 3, subfamily A, polypeptide 4/5 (3A4/5) inhibitor
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor
Has received concomitant treatment with a strong inhibitor or inducer of cytochrome P450 (CYP)3A4/5 within 7 days of first receipt of DS-3201b
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
Requires treatment with a strong CYP 3A inhibitor
